Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings Healthy, Genzyme’s Bigger-Batch Myozome Plant On Track For Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

2,000-liter version of Pompe therapy, rebranded as Lumizyme, due for action later this month.

You may also be interested in...



Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says

GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.

Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says

GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.

FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says

The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel